Troy Wichterman Sells 1,032 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

Key Points

• Troy Wichterman, CFO of BioLife Solutions, sold 1,032 shares of the company's stock at an average price of $26.83, totaling $27,688.56, resulting in a 0.56% decrease in his holdings.
• BioLife Solutions reported a loss of $0.33 per share in its latest earnings, significantly missing analysts' expectations, while revenue was higher than predicted at $25.42 million.
• Following various investment reports, BioLife Solutions currently holds a consensus rating of "Buy" with an average target price of $31.29.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 1,032 shares of the company's stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $26.83, for a total value of $27,688.56. Following the completion of the sale, the chief financial officer owned 184,186 shares in the company, valued at $4,941,710.38. This represents a 0.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, August 26th, Troy Wichterman sold 590 shares of BioLife Solutions stock. The stock was sold at an average price of $25.44, for a total value of $15,009.60.
• On Monday, July 7th, Troy Wichterman sold 877 shares of BioLife Solutions stock. The stock was sold at an average price of $22.27, for a total value of $19,530.79.

BioLife Solutions Stock Up 1.1%

Shares of BLFS stock traded up $0.29 during trading hours on Monday, reaching $25.80. The company's stock had a trading volume of 403,794 shares, compared to its average volume of 478,382. The firm's 50 day simple moving average is $23.47 and its 200-day simple moving average is $23.29. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -214.98 and a beta of 1.78. BioLife Solutions, Inc. has a fifty-two week low of $19.10 and a fifty-two week high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The business had revenue of $25.42 million during the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. Sell-side analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BLFS has been the topic of several recent research reports. Wall Street Zen downgraded BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Stephens started coverage on BioLife Solutions in a report on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 price objective on the stock. Zacks Research raised BioLife Solutions to a "strong-buy" rating in a research report on Monday, August 11th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $32.00 target price (up from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $31.29.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of BioLife Solutions in the fourth quarter worth $31,000. State of Wyoming increased its stake in BioLife Solutions by 353.1% in the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 1,490 shares during the last quarter. US Bancorp DE increased its stake in BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 1,528 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of BioLife Solutions by 12.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider's stock valued at $83,000 after buying an additional 441 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after purchasing an additional 663 shares during the period. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.